What Targeted Therapies Exist for EGFR-Driven Cancers?
Several targeted therapies have been developed to inhibit EGFR in cancers where it is implicated. These include tyrosine kinase inhibitors (TKIs) like gefitinib, erlotinib, and osimertinib, which block the kinase activity of EGFR, thereby inhibiting downstream signaling pathways that promote tumor growth. Monoclonal antibodies such as cetuximab and panitumumab are also used to target EGFR on the surface of cancer cells, preventing ligand binding and receptor activation.
